Catalyst Event
Johnson & Johnson (JNJ) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/18/2026, 12:00:00 AM
The U.S. FDA approved Icotyde on March 18, 2026, a once-daily oral treatment for moderate-to-severe plaque psoriasis, which has a multi-billion dollar peak sales potential.
Korean Translation
2026년 3월 18일, 미국 FDA는 수십억 달러의 최고 매출 잠재력을 가진 중등도에서 중증의 판상 건선에 대한 1일 1회 경구 치료제인 이코타이드(Icotyde)를 승인함
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
First quarter 2026 earnings release and conference call scheduled.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck is scheduled to release its Q1 2026 financial results before the market opens. Earnings releases typically cause significant price volatility, justifying a Medium importance, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
First quarter 2026 financial results and conference call scheduled for 2026-04-30. Routine earnings announcements typically result in minor price fluctuations (Low importance) scheduled.
4/30/2026, 12:00:00 AM
Medpace Holdings Inc (MEDP) · Earnings Release
First quarter 2026 financial results to be reported after market close on April 22, 2026. Importance is estimated as High as earnings releases typically cause significant price volatility, scheduled.
4/22/2026, 12:00:00 AM